Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018)
Omeros (OMER) reported Non-Current Deffered Revenue of $8.2 million for Q4 2018, down 6.21% on a YoY basis from $8.7 million in Q4 2017, and down 1.78% sequentially from $8.3 million in Q3 2018.
Omeros (OMER) Non-Current Deffered Revenue (2012 - 2018) Analysis & Trends
Omeros (OMER) has 7 years of Non-Current Deffered Revenue data on file, last reported at $8.2 million in Q4 2018.
- For the quarter ending Q4 2018, Non-Current Deffered Revenue fell 6.21% year-over-year to $8.2 million; the trailing twelve-month figure through Dec 2018 stood at $8.2 million (down 6.21% YoY), and the FY2018 full-year result was $8.2 million, down 6.21% from the prior year.
- Non-Current Deffered Revenue slipped to $8.2 million in Q4 2018, from $8.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $9.2 million in Q1 2016 to a low of $8.2 million in Q4 2018.
- A 5-year average of $8.9 million and a median of $9.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue jumped 122.99% in 2014 and retreated 6.21% in 2018, its largest moves.
- Tracing OMER's Non-Current Deffered Revenue over 5 years: stood at $9.0 million in 2014, then rose by 1.73% to $9.2 million in 2015, then dropped by 0.71% to $9.1 million in 2016, then fell by 4.64% to $8.7 million in 2017, then dropped by 6.21% to $8.2 million in 2018.
- Business Quant data shows OMER's Non-Current Deffered Revenue at $8.2 million in Q4 2018, $8.3 million in Q3 2018, and $8.5 million in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Omeros | 739.31 Mn | 739.31 Mn | 9.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 8.18 Mn |
| Sep 30, 2018 | 8.33 Mn |
| Jun 30, 2018 | 8.45 Mn |
| Mar 31, 2018 | 8.58 Mn |
| Dec 31, 2017 | 8.72 Mn |
| Sep 30, 2017 | 8.84 Mn |
| Jun 30, 2017 | 8.94 Mn |
| Mar 31, 2017 | 9.04 Mn |
| Dec 31, 2016 | 9.14 Mn |
| Sep 30, 2016 | 9.19 Mn |
| Jun 30, 2016 | 9.21 Mn |
| Mar 31, 2016 | 9.22 Mn |
| Dec 31, 2015 | 9.21 Mn |
| Sep 30, 2015 | 9.17 Mn |
| Jun 30, 2015 | 9.13 Mn |
| Mar 31, 2015 | 9.09 Mn |
| Dec 31, 2014 | 9.05 Mn |
| Sep 30, 2014 | 8.94 Mn |
| Jun 30, 2014 | 8.67 Mn |
| Mar 31, 2014 | 8.41 Mn |